Skip to main content
main-content

01.05.2014 | Poster presentation | Sonderheft 1/2014 Open Access

Journal of Translational Medicine 1/2014

Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-dependent advanced solid tumors: preliminary results

Zeitschrift:
Journal of Translational Medicine > Sonderheft 1/2014
Autoren:
Richard Kefford, Ryan J Sullivan, Wilson H Miller Jr, Elena M Elez, Daniel Tan, Kevin B Kim, Georgina V Long, Keith T Flaherty, David Tai, Simone Stutvoet, Heiko Maacke, Matt Whiley, Laure Moutouh-de Parseval, Josep Tabernero

Without Abstract

Über diesen Artikel

Weitere Artikel der Sonderheft 1/2014

Journal of Translational Medicine 1/2014Zur Ausgabe